Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q3 FY25 results · Oct–Dec 2024
Glenmark Pharmaceuticals reported revenue from operations of ₹3,387.55 crore (up 35.1% from Q3 FY24) and net profit of ₹348.03 crore for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,387.55 | 2,506.70 | +35.1% | 3,433.80 | −1.3% |
| Other income | 31.13 | 45.41 | −31.5% | 39.42 | −21.0% |
| Total income | 3,418.68 | 2,552.11 | +34.0% | 3,473.21 | −1.6% |
| Profit before tax | 456.33 | (521.38) | Turned profit | 472.57 | −3.4% |
| Net profit for the period | 348.03 | (330.82) | Turned profit | 354.49 | −1.8% |
| EPS, basic (₹) | 12.33 | (12.45) | Turned profit | 12.55 | −1.8% |
| Net margin (%) | 10.3 | -13.2 | 10.3 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,251.28 | 1,365.10 | +64.9% | 2,636.10 | −14.6% |
| Other income | 129.19 | 258.81 | −50.1% | 83.08 | +55.5% |
| Total income | 2,380.47 | 1,623.91 | +46.6% | 2,719.18 | −12.5% |
| Profit before tax | 559.49 | (75.50) | Turned profit | 795.06 | −29.6% |
| Net profit for the period | 413.80 | (20.41) | Turned profit | 595.06 | −30.5% |
| EPS, basic (₹) | 14.66 | (0.72) | Turned profit | 21.09 | −30.5% |
| Net margin (%) | 18.4 | -1.5 | 22.6 |
Consolidated
- Filed with BSE
- 14 Feb 2025, 20:13 IST
- Board meeting
- 14 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 Feb 2025, 20:13 IST
- Board meeting
- 14 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE